McEwen v. Baltimore Washington Medical Center Inc. , 404 F. App'x 789 ( 2010 )


Menu:
  •                               UNPUBLISHED
    UNITED STATES COURT OF APPEALS
    FOR THE FOURTH CIRCUIT
    No. 09-2141
    MARK MCEWEN; DENISE MCEWEN,
    Plaintiffs – Appellants,
    v.
    BALTIMORE WASHINGTON MEDICAL CENTER INCORPORATED, d/b/a
    Baltimore   Washington   Medical   Center;   MICHAEL    BOND;
    BALTIMORE WASHINGTON EMERGENCY PHYSICIANS INCORPORATED,
    Defendants – Appellees.
    Appeal from the United States District Court for the District of
    Maryland, at Baltimore.     J. Frederick Motz, District Judge.
    (1:08-cv-01492-JFM)
    Argued:   October 27, 2010             Decided:   December 14, 2010
    Before KING and DUNCAN, Circuit Judges, and Bobby R. BALDOCK,
    Senior Circuit Judge of the United States Court of Appeals for
    the Tenth Circuit, sitting by designation.
    Affirmed by unpublished per curiam opinion.
    ARGUED: Andrew Howard Baida, ROSENBERG, MARTIN & GREENBERG, LLP,
    Baltimore, Maryland, for Appellants.     Derek M. Stikeleather,
    GOODELL DEVRIES LEECH & DANN, LLP, Baltimore, Maryland, for
    Appellees.   ON BRIEF: Caroline L. Hecker, ROSENBERG, MARTIN &
    GREENBERG, LLP, Baltimore, Maryland, for Appellants.    Susan T.
    Preston, GOODELL DEVRIES LEECH & DANN, LLP, Baltimore, Maryland,
    for Appellees.
    Unpublished opinions are not binding precedent in this circuit.
    2
    PER CURIAM:
    This appeal arises from a district court’s exclusion of
    appellants       Mark    and    Denise       McEwens’       (“the   McEwens”)       expert
    medical witnesses and subsequent grant of summary judgment in
    favor of appellees Baltimore Washington Medical Center, Inc., et
    al.   (“BWMC”).          The    McEwens       argue     that    the      district    court
    misapplied the standard governing the admissibility of expert
    scientific       testimony,     as    laid    out     in    Daubert      v.   Merrell   Dow
    Pharmaceuticals, Inc., 
    509 U.S. 579
     (1993).                           For the reasons
    described below, we affirm.
    I.
    A.
    We briefly summarize the pertinent facts.                          On November 13,
    2005, Mark McEwen was brought by ambulance to BWMC’s emergency
    room in Maryland, complaining of dizziness, vomiting, slurred
    speech, weakness, and fainting.                   A physician diagnosed McEwen
    with gastroenteritis and treated him with antinausea medication
    and hydration.          McEwen’s condition improved and he was released
    from the hospital in the early morning of November 14.
    On   the    evening      of    November     15,      McEwen   flew      to   Orlando,
    Florida.     He felt unsteady during the flight and, upon arrival,
    was   brought      to   a   Florida      hospital,         where    he    complained    of
    headache, unsteadiness, and nausea.                     Around 11:45 p.m., McEwen
    3
    developed additional symptoms, including weakness on the left
    side of his body.           An MRI revealed that McEwen had suffered a
    stroke.       The attending doctor treated McEwen with Lovenox 1 and
    aspirin and an increase in his intravenous fluids.                      Over the
    next four hours, his condition improved dramatically.
    B.
    In June 2008, the McEwens sued BWMC.                They claimed that
    doctors’ negligent failure to properly treat Mark McEwen with
    anticoagulant medication on November 13 caused his stroke on
    November 15.          The McEwens employed two physicians to provide
    expert opinions on their behalf: Dr. Cathy Helgason and Dr. Jon
    Peters.
    Doctors Helgason and Peters separately concluded that BWMC
    physicians        should   have   recognized    that   McEwen    was   exhibiting
    signs of a stroke on November 13 and that treatment with the
    type of medication that he was administered on November 15 would
    have averted his second stroke.               Dr. Helgason based her opinion
    on her knowledge of the “pathophysiology of stroke” and on the
    fact       that   McEwen   improved   after    receiving   the   medication   on
    November 15.         J.A. 130.     Dr. Peters anchored his assessment in
    1
    Lovenox contains enoxaparin, an anticlotting agent.  See
    Stedman’s Medical Dictionary 645, 874 (28th ed. 2006); see also
    Aventis Pharma S.A. v. Amphastar Pharm., Inc., 
    525 F.3d 1334
    ,
    1336 (Fed. Cir. 2008).
    4
    his   evaluation       of   McEwen’s     medical       records       from   the    Florida
    hospital, which showed improvement as a result of the course of
    treatment he received there.
    In July 2009, BWMC moved to exclude both experts’ medical
    causation testimony, urging that their statements failed to meet
    the   threshold        requirements      of       Daubert    and     Federal      Rule    of
    Evidence 702.          BWMC simultaneously moved for summary judgment.
    The district court held a Daubert hearing in September 2009.
    After hearing from both sides, the district court granted BWMC’s
    motions. 2
    The district court concluded that neither of the McEwens’
    experts had satisfied Daubert’s standard for admissibility.                              The
    court     expressed         particular            concern     over      the       experts’
    methodology.       The court noted that absent any reliance on or
    support from the relevant medical literature, in effect the only
    basis     for    the    experts’    conclusions             was     “a[n]   ipse    dixit
    statement of a clinician saying that I think causation has been
    proved, which is simply not sufficient as a matter of law.”
    J.A. 980.       The court observed that the physicians’ testimony was
    further      undermined     by   their    failure       to        account   for    medical
    literature that suggested that the medications at issue were not
    2
    The district court also granted BWMC’s motion to strike
    studies belatedly cited by Dr. Peters.      The McEwens have not
    appealed that ruling, and so we do not discuss it further.
    5
    “sufficiently        beneficial    [in     the    short    term]     to    prevent     a
    stroke.”      
    Id.
    Having concluded that the medical experts had not satisfied
    the    Daubert       standard,     the     district       court     excluded     their
    testimony.       Since the medical testimony was essential to proving
    causation, the district court granted BWMC’s motion for summary
    judgment.       This appeal followed.
    II.
    The    McEwens    challenge    the      district    court’s     exclusion      of
    their experts’ testimony.            They claim, in particular, that the
    doctors’ views were sufficiently grounded in “well-established
    and reliable principles and methodologies,” Appellant’s Br. at
    13, and that the district court erred by concluding otherwise.
    We review the district court’s application of Daubert for abuse
    of discretion, Anderson v. Westinghouse Savannah River Co., 
    406 F.3d 248
    , 260 (4th Cir. 2005), and find none.
    Daubert clarified “that it is the duty of the trial court
    to    perform    the    gatekeeping       function    with    respect       to   expert
    testimony:       ‘the   trial     judge    must    ensure     that    any    and     all
    scientific testimony or evidence admitted is not only relevant,
    but reliable.’”          United States v. Prince-Oyibo, 
    320 F.3d 494
    ,
    498    (4th     Cir.    2003)    (quoting       Daubert,     
    509 U.S. at 589
    ).
    Although        we      have      recognized         that,         under     Daubert,
    6
    “epidemiological studies are not necessarily required to prove
    causation,” a proposed expert must show that “the methodology
    employed . . . in reaching his or her conclusion is sound.”
    Benedi    v.    McNeil-P.P.C.,         Inc.,      
    66 F.3d 1378
    ,   1384    (4th    Cir.
    1995).
    The       district       court     did    not     abuse    its    discretion      by
    excluding the testimony of Doctors Helgason and Peters.                            As the
    district court explained, the physicians failed to present a
    reliable       basis   for    their     conclusions.          The   fact    that   McEwen
    reacted favorably after treatment with anticoagulant drugs on
    November 15 says little to nothing about the probable effect of
    such drugs on November 13, particularly when McEwen appears to
    have also responded well to the treatment he did receive at
    BWMC,    which     did    not    include       anticoagulants.             Further,   the
    McEwens’       experts    failed       to   meaningfully       account      for    medical
    literature       at    odds     with    their      testimony,       declaring      without
    explanation that the studies cited by BWMC did not apply to
    McEwen.        “[N]othing in either Daubert or the Federal Rules of
    Evidence requires a district court to admit opinion evidence
    that is connected to existing data only by the ipse dixit of the
    expert.”       Gen. Elec. Co. v. Joiner, 
    522 U.S. 136
    , 146 (1997).
    The McEwens’ assertion that the district court applied the
    wrong standard is unavailing.                  The district court’s thoroughly
    reasoned oral decision plainly reflects its determination that
    7
    the McEwens had not carried their burden of presenting evidence
    “from   which   the   court   c[ould]   determine   that   the   proffered
    testimony [wa]s properly admissible.”        Md. Cas. Co. v. Therm-O-
    Disc, Inc., 
    137 F.3d 780
    , 783 (4th Cir. 1998).
    III.
    We have reviewed the McEwens’ remaining claims and find
    them to be without merit.        For the foregoing reasons we affirm
    the district court’s exclusion of the McEwens’ experts and its
    grant of summary judgment.
    AFFIRMED
    8